PMID- 32007322
OWN - NLM
STAT- MEDLINE
DCOM- 20200826
LR  - 20210602
IS  - 2174-2049 (Electronic)
IS  - 2174-2049 (Linking)
VI  - 38
IP  - 11
DP  - 2019 Nov
TI  - Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: 
      Contemporaneous Portuguese cross-sectional data.
PG  - 809-814
LID - S0870-2551(20)30007-X [pii]
LID - 10.1016/j.repc.2019.02.015 [doi]
AB  - INTRODUCTION: The standard of care for acute ST-elevation myocardial infarction 
      (STEMI) includes the activation of a STEMI care network, the administration of 
      adjuvant medical therapy, and reperfusion through primary percutaneous coronary 
      intervention (PCI). While primary PCI is nowadays the first option for the 
      treatment of patients with STEMI, antithrombotic therapy, including antiplatelet 
      and anticoagulant agents, is the cornerstone of pharmacological treatment to 
      optimize their clinical outcomes. OBJECTIVE: The aim of this study was to 
      describe contemporaneous real-world patterns of use of antithrombotic treatments 
      in Portugal for STEMI patients undergoing primary PCI. METHODS: An observational, 
      retrospective cross-sectional study was performed for the year 2016, based on 
      data from two national registries: the Portuguese Registry on Acute Coronary 
      Syndromes (ProACS) and the Portuguese Registry on Interventional Cardiology 
      (PRIC). Data on oral antiplatelet and procedural intravenous antithrombotic drugs 
      were retrieved. RESULTS: In 2016, the ProACS enrolled 534 STEMI patients treated 
      with primary PCI, while the PRIC registry reported data on 2625 STEMI patients. 
      Of these, 99.6% were treated with aspirin and 75.6% with dual antiplatelet 
      therapy (mostly clopidogrel). GP IIb/IIIa inhibitors (mostly abciximab) were used 
      in 11.6% of cases. Heparins were used in 80% of cases (78% unfractionated heparin 
      [UFH] and 2% low molecular weight heparin). None of the patients included in the 
      registry were treated with cangrelor, prasugrel or bivalirudin. Missing data are 
      one of the main limitations of the registries. CONCLUSIONS: In 2016, according to 
      data from these national registries, almost all patients with STEMI were treated 
      with aspirin and 76% with dual antiplatelet agents, mostly clopidogrel. GP 
      IIb/IIIa inhibitors were used in few patients, and UFH was the most prevalent 
      parenteral anticoagulant drug.
CI  - Copyright (c) 2020 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier 
      Espana, S.L.U. All rights reserved.
FAU - Caldeira, Daniel
AU  - Caldeira D
AD  - Cardiology Department, Hospital Garcia de Orta, Almada, Portugal; Laboratorio de 
      Farmacologia Clinica e Terapeutica, CCUL, CAML, Faculdade de Medicina, 
      Universidade de Lisboa, Portugal. Electronic address: dgcaldeira@hotmail.com.
FAU - Pereira, Helder
AU  - Pereira H
AD  - Cardiology Department, Hospital Garcia de Orta, Almada, Portugal.
FAU - Marques, Ana
AU  - Marques A
AD  - Cardiology Department, Hospital Garcia de Orta, Almada, Portugal.
FAU - Alegria, Sofia
AU  - Alegria S
AD  - Cardiology Department, Hospital Garcia de Orta, Almada, Portugal.
FAU - Calisto, Joao
AU  - Calisto J
AD  - Centro Hospitalar e Universitario de Coimbra - HUC, Coimbra, Portugal.
FAU - Silva, Pedro Canas da
AU  - Silva PCD
AD  - Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte EPE, Lisboa, Portugal.
FAU - Ribeiro, Vasco Gama
AU  - Ribeiro VG
AD  - Centro Hospitalar de Vila Nova de Gaia/Espinho - Hospital Eduardo Santos Silva, 
      Porto, Portugal.
FAU - Silva, Joao Carlos
AU  - Silva JC
AD  - Centro Hospitalar de Sao Joao, Porto, Portugal.
FAU - Seixo, Filipe
AU  - Seixo F
AD  - Hospital de Sao Bernardo, Centro Hospitalar de Setubal, Portugal.
FAU - Abreu, Pedro Farto E
AU  - Abreu PFE
AD  - Hospital Professor Doutor Fernando da Fonseca, Amadora, Portugal.
FAU - Teles, Rui Campante
AU  - Teles RC
AD  - Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal.
FAU - Fernandes, Renato
AU  - Fernandes R
AD  - Hospital do Espirito Santo, Evora, Portugal.
FAU - Carvalho, Henrique Cyrne
AU  - Carvalho HC
AD  - Hospital de Santo Antonio, Centro Hospitalar do Porto, Porto, Portugal.
CN  - investigators of the Portuguese Registry of Acute Coronary Syndromes (ProACS), 
      investigators of the Portuguese Registry on Interventional Cardiology (PRIC)
LA  - eng
LA  - por
PT  - Journal Article
PT  - Observational Study
DEP - 20200129
PL  - Spain
TA  - Rev Port Cardiol (Engl Ed)
JT  - Revista portuguesa de cardiologia
JID - 101770878
RN  - 0 (Fibrinolytic Agents)
SB  - IM
CIN - Rev Port Cardiol (Engl Ed). 2019 Nov;38(11):815-816. PMID: 31987709
MH  - Administration, Oral
MH  - Aged
MH  - Chemotherapy, Adjuvant
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Fibrinolytic Agents/administration & dosage/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention
MH  - Portugal
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *ST Elevation Myocardial Infarction/drug therapy/epidemiology/surgery
OTO - NOTNLM
OT  - Adjuvant
OT  - Adjuvante
OT  - Antiagregante
OT  - Anticoagulant
OT  - Anticoagulante
OT  - Antiplatelet
OT  - Antithrombotic
OT  - Antitrombotico
OT  - Enfarte do miocardio
OT  - Myocardial infarction
EDAT- 2020/02/03 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/02/03 06:00
PHST- 2018/01/01 00:00 [received]
PHST- 2019/01/25 00:00 [revised]
PHST- 2019/02/27 00:00 [accepted]
PHST- 2020/02/03 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
PHST- 2020/02/03 06:00 [entrez]
AID - S0870-2551(20)30007-X [pii]
AID - 10.1016/j.repc.2019.02.015 [doi]
PST - ppublish
SO  - Rev Port Cardiol (Engl Ed). 2019 Nov;38(11):809-814. doi: 
      10.1016/j.repc.2019.02.015. Epub 2020 Jan 29.